Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BioCardia ( (BCDA) ) just unveiled an update.
On November 24, 2025, BioCardia, Inc. announced the appointment of Farhan Shahab as Vice President of Quality. Shahab brings over 25 years of experience in quality management and regulatory roles from various medical and health companies. His expertise is expected to enhance BioCardia’s efforts in commercializing its investigational products, potentially accelerating their market readiness and strengthening the company’s leadership team.
The most recent analyst rating on (BCDA) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.
Spark’s Take on BCDA Stock
According to Spark, TipRanks’ AI Analyst, BCDA is a Neutral.
BioCardia’s overall stock score is primarily impacted by its weak financial performance and valuation. While there are positive developments in clinical trials and regulatory progress, these are overshadowed by ongoing financial instability and bearish technical indicators.
To see Spark’s full report on BCDA stock, click here.
More about BioCardia
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. The company’s biotherapeutic platforms include CardiAMP autologous and CardiALLO allogeneic cell therapies, with three clinical stage product candidates in development, enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
Average Trading Volume: 583,697
Technical Sentiment Signal: Sell
Current Market Cap: $14.54M
For an in-depth examination of BCDA stock, go to TipRanks’ Overview page.